Professionals reviewing the SOP together.

This standard operating procedure (SOP) is recommended for transitioning clinical trials from the EU CTD to the EU CTR using the Clinical Trials Information System CTIS. It applies to all ongoing interventional clinical trials authorized under the CTD with at least one active site in the EU/EEA as of Jan. 30, 2025, as well as those trials on EudraCT requiring an amendment subject to approval by the member states (e.g., adding sites in a new member state) before Jan. 30, 2025.


Related resources

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
eBook
薬事規制関連支援サービス

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency

Digital representation of the globe.
MAR 01, 2023
Whitepaper
薬事規制関連支援サービス

Global Clinical Trial Disclosure: What Noncompliance Penalties Are in Place, & How They Are Enforced

Industry groups and transparency advocates call for enforcing clinical trial disclosure noncompliance penalties. But are regulatory agencies doing so?

Person with glasses looking at paperwork.
SEP 26, 2023
Article
薬事規制関連支援サービス

Transitioning Trials to the EU Clinical Trials Regulation

The transition from the EU Clinical Trials Directive (CTD) to the new Clinical Trials Regulation (CTR) represents a significant shift in how trials will be conducted across Europe.